Analysts Set Roche Holding AG (OTCMKTS:RHHBY) Target Price at $57.00

Shares of Roche Holding AG (OTCMKTS:RHHBY) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and three have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $57.00.

RHHBY has been the topic of a number of research reports. Zacks Research lowered shares of Roche from a “hold” rating to a “strong sell” rating in a research report on Friday, December 5th. JPMorgan Chase & Co. raised Roche from an “underweight” rating to a “neutral” rating in a research report on Monday, December 8th. Jefferies Financial Group cut Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. Deutsche Bank Aktiengesellschaft upgraded Roche from a “sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of Roche in a research note on Tuesday, December 2nd.

Roche Stock Up 1.9%

RHHBY stock opened at $51.23 on Wednesday. Roche has a 12 month low of $34.17 and a 12 month high of $51.49. The firm’s 50-day moving average is $45.95 and its 200 day moving average is $42.66.

Hedge Funds Weigh In On Roche

Several institutional investors have recently bought and sold shares of the business. Boston Common Asset Management LLC raised its stake in Roche by 1.9% in the third quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company’s stock worth $15,049,000 after buying an additional 6,720 shares in the last quarter. OLD National Bancorp IN raised its position in shares of Roche by 2.9% in the 2nd quarter. OLD National Bancorp IN now owns 261,317 shares of the company’s stock worth $10,604,000 after acquiring an additional 7,326 shares in the last quarter. Altrius Capital Management Inc lifted its stake in shares of Roche by 4.0% during the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company’s stock worth $8,290,000 after purchasing an additional 7,659 shares during the last quarter. Bard Financial Services Inc. boosted its position in Roche by 1.3% during the third quarter. Bard Financial Services Inc. now owns 138,650 shares of the company’s stock valued at $5,797,000 after purchasing an additional 1,800 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in Roche by 1.1% during the second quarter. Rhumbline Advisers now owns 108,480 shares of the company’s stock valued at $4,422,000 after purchasing an additional 1,228 shares in the last quarter.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.